<DOC>
	<DOC>NCT01300078</DOC>
	<brief_summary>This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United States.</brief_summary>
	<brief_title>A Clinical Trial Assessing Safety of MF101 for Hot Flushes</brief_title>
	<detailed_description>MF101 is an oral, non-hormonal, botanical agent being investigated for the treatment of menopausal hot flashes.</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Inclusion Criteria (partial list): Postmenopausal women aged 4065 years. Provide informed consent. Currently receive medical care from a health care provider. Other inclusions apply. Exclusion Criteria (partial list): History of malignancy other than nonmelanoma skin cancer or cervical cancer that was diagnosed and fully treated less than 5 years before screening. Unexplained uterine bleeding within 6 months prior to Screening. History of deep vein thrombosis or pulmonary embolism. Active liver disease or a history of impaired. Active gallbladder disease. Other exclusions apply.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hot Flashes</keyword>
	<keyword>Hot Flushes</keyword>
	<keyword>Vasomotor Symptoms</keyword>
	<keyword>Menopausal Symptoms</keyword>
</DOC>